Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorCREUZE, Alexandre
dc.contributor.authorFOK-CHEONG, Thomas
dc.contributor.authorWEIR, Adam
dc.contributor.authorBORDES, Philippe
dc.contributor.authorREBOUL, Gilles
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGLIZE, Bertrand
ORCID: 0000-0001-9618-2088
IDREF: 178853267
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDE SEZE, Mathieu
dc.date.accessioned2022-10-31T11:22:43Z
dc.date.available2022-10-31T11:22:43Z
dc.date.issued2022-09-05
dc.identifier.issn1536-3724 (Electronic) 1050-642X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/170173
dc.description.abstractEnBACKGROUND: Adductor-related groin pain (ARGP) is the most common groin injury in athletes. If conservative treatment fails, then adductor tenotomy to relieve tension can be considered. The use of botulinum toxin A (BoNT-A) has shown good results in other musculoskeletal pathologies. OBJECTIVE: Assess the effectiveness of BoNT-A injections in ARGP in cases where usual treatment has failed. DESIGN: Retrospective cohort study. SETTING: Orthopedic Medicine and Rehabilitation Unit, University of Bordeaux. PARTICIPANTS: Fifty patients treated by BoNT-A injection in ARGP after failure of medical and/or surgical treatment were included in this study. INTERVENTIONS: One or several adductor muscles were injected with BoNT-A, according to clinical evaluation using ultrasound and electrical stimulation guidance. Patients were followed up at 1, 3, 6, and 12 months. MAIN OUTCOME MEASURES: The primary assessment criterion was the improvement of Hip and Groin Outcome Score subscales at day 30. Secondary outcomes included pain intensity and impact on sport, work, and quality of life (QoL), the Blazina scale, and side effects. RESULTS: All the first 50 injected patients (45 male and 5 female patients) were included. A significant improvement was noted regarding the majority of Hip and Groin Outcome Score subscales at day 30 (P < 0.05). Pain intensity and its impacts were both significantly reduced (P < 0.001): less sport and professional disability and lower impact on QoL. Severity of symptoms assessed by the Blazina scale was significantly reduced (P < 0.001). The improvements remained significant until 1-year postinjection. CONCLUSIONS: BoNT-A is promising as a new treatment for ARGP but should be fully assessed in a randomized controlled trial.
dc.language.isoENen_US
dc.title.enNovel Use of Botulinum Toxin in Long-Standing Adductor-Related Groin Pain: A Case Series
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/jsm.0000000000001066en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36070357en_US
bordeaux.journalClinical Journal of Sport Medicineen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamACTIVE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03835058
hal.version1
hal.date.transferred2022-10-31T11:22:56Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Clinical%20Journal%20of%20Sport%20Medicine&amp;rft.date=2022-09-05&amp;rft.eissn=1536-3724%20(Electronic)%201050-642X%20(Linking)&amp;rft.issn=1536-3724%20(Electronic)%201050-642X%20(Linking)&amp;rft.au=CREUZE,%20Alexandre&amp;FOK-CHEONG,%20Thomas&amp;WEIR,%20Adam&amp;BORDES,%20Philippe&amp;REBOUL,%20Gilles&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée